Current positioning and future development of belantamab mafodotin and other antibody-drug conjugates to treat multiple myeloma
{{output}}
The treatment of Multiple myeloma (MM) has been revolutionized by the advent of immunotherapies. Monoclonal antibodies targeting specific markers greatly contributed to patients' outcome improvement. Antibodies can be conjugated with a toxic payload to exert ... ...
